Literature DB >> 18265413

Developmental impairments of select neurotransmitter systems in brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis.

Philipp Herrmann1, Caroline Druckrey-Fiskaaen, Elena Kouznetsova, Katrin Heinitz, Marina Bigl, Susan L Cotman, Reinhard Schliebs.   

Abstract

The neuronal ceroidlipofuscinoses (NCL) are a group of neurodegenerative disorders and are the most common lysosomal storage diseases of infancy and childhood. Juvenile NCL is caused by CLN3 mutation, producing retinal degeneration, uncontrollable seizures, cognitive and motor decline, and early death before the age of 30 years. To study the pathogenetic mechanisms of the disease, Cln3 knock-in mice (Cln3(Deltaex7/8)) have been generated, which reproduce the 1.02-kb deletion in the CLN3 gene observed in more than 85% of juvenile NCL patients. To characterize the impact of the common Cln3 mutation on development of autofluorescent storage material, gliosis, glucose metabolism, oxidative stress, and transmitter receptors during postnatal brain maturation, brain tissue of Cln3(Deltaex7/8) mice at the ages of 3, 4, 5, 6, 9, and 19 months was subjected to immunocytochemistry to label gliotic markers and nitric oxide synthases; photometric assays to assess enzyme activities of glycolysis and antioxidative defense systems; and level of reactive nitrogen species as well as quantitative receptor autoradiography to detect select cholinergic, glutamatergic, and GABAergic receptor subtypes. The developmental increase in cerebral cortical autofluorescent lipofuscin-like deposition is accompanied by a significant astro- and microgliosis, increased activities of lactate dehydrogenase and phosphofructokinase, decreased level of glutathione peroxidase, enhanced amount of reactive nitrogen species, and lowered binding levels of N-methyl-D-aspartate- and M1-muscarinic acetylcholine receptors in select brain regions but hardly in GABA(A) receptor sites compared with wild-type mice. Detailed elucidation of the sequence of pathological events during postnatal development highlights new potential strategies for symptomatic treatment of the disease. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18265413     DOI: 10.1002/jnr.21630

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  12 in total

1.  The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking.

Authors:  Susan L Cotman; John F Staropoli
Journal:  Clin Lipidol       Date:  2012-02

2.  Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration.

Authors:  Cristy A Ku; Sarah Hull; Gavin Arno; Ajoy Vincent; Keren Carss; Robert Kayton; Douglas Weeks; Glenn W Anderson; Ryan Geraets; Camille Parker; David A Pearce; Michel Michaelides; Robert E MacLaren; Anthony G Robson; Graham E Holder; Elise Heon; F Lucy Raymond; Anthony T Moore; Andrew R Webster; Mark E Pennesi
Journal:  JAMA Ophthalmol       Date:  2017-07-01       Impact factor: 7.389

Review 3.  Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease).

Authors:  Madhu M Ouseph; Mark E Kleinman; Qing Jun Wang
Journal:  Ann N Y Acad Sci       Date:  2016-01-08       Impact factor: 5.691

4.  Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation.

Authors:  Kakulavarapu V Rama Rao; Tammy Kielian
Journal:  Clin Exp Neuroimmunol       Date:  2015-08-03

5.  Neurodevelopmental delay in the Cln3Deltaex7/8 mouse model for Batten disease.

Authors:  N S Osório; B Sampaio-Marques; C-H Chan; P Oliveira; D A Pearce; N Sousa; F Rodrigues
Journal:  Genes Brain Behav       Date:  2009-02-19       Impact factor: 3.449

6.  Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene.

Authors:  Dolan Sondhi; Emma C Scott; Alvin Chen; Neil R Hackett; Andrew M S Wong; Agnieszka Kubiak; Hemanth R Nelvagal; Yewande Pearse; Susan L Cotman; Jonathan D Cooper; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-03-04       Impact factor: 5.695

7.  Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system.

Authors:  John F Staropoli; Larissa Haliw; Sunita Biswas; Lillian Garrett; Sabine M Hölter; Lore Becker; Sergej Skosyrski; Patricia Da Silva-Buttkus; Julia Calzada-Wack; Frauke Neff; Birgit Rathkolb; Jan Rozman; Anja Schrewe; Thure Adler; Oliver Puk; Minxuan Sun; Jack Favor; Ildikó Racz; Raffi Bekeredjian; Dirk H Busch; Jochen Graw; Martin Klingenspor; Thomas Klopstock; Eckhard Wolf; Wolfgang Wurst; Andreas Zimmer; Edith Lopez; Hayat Harati; Eric Hill; Daniela S Krause; Jolene Guide; Ella Dragileva; Evan Gale; Vanessa C Wheeler; Rose-Mary Boustany; Diane E Brown; Sylvie Breton; Klaus Ruether; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Susan L Cotman
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

8.  Loss of Cln5 causes altered neurogenesis in a mouse model of a childhood neurodegenerative disorder.

Authors:  Ekaterina Savchenko; Yajuvinder Singh; Henna Konttinen; Katarina Lejavova; Laura Mediavilla Santos; Alexandra Grubman; Virve Kärkkäinen; Velta Keksa-Goldsteine; Nikolay Naumenko; Pasi Tavi; Anthony R White; Tarja Malm; Jari Koistinaho; Katja M Kanninen
Journal:  Dis Model Mech       Date:  2017-07-21       Impact factor: 5.758

9.  Evidence for aberrant astrocyte hemichannel activity in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL).

Authors:  Maria Burkovetskaya; Nikolay Karpuk; Juan Xiong; Megan Bosch; Michael D Boska; Hideyuki Takeuchi; Akio Suzumura; Tammy Kielian
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

10.  Searching for novel biomarkers using a mouse model of CLN3-Batten disease.

Authors:  Derek Timm; Jacob T Cain; Ryan D Geraets; Katherine A White; Seung Yon Koh; Tammy Kielian; David A Pearce; Michelle L Hastings; Jill M Weimer
Journal:  PLoS One       Date:  2018-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.